SCHEMBL9825632

SCHEMBL9825632

CCCNc1cc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.47
CYP2A6 P11509 4/20 0.46
ADRB2 P07550 1/20 0.46
ASIC3 Q9UHC3 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
DRD2 P14416 1/20 0.40
SLC6A4 P31645 1/20 0.40
HDAC3 O15379 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
NCOR2 Q9Y618 1/20 0.40
AGXT P21549 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9826403 0.90 RAB9A (0.55) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL26054604 0.87 RAB9A (0.49) RAB9ACYP2A6ADRB2
SCHEMBL5732542 0.85 CYP2A6 (0.49) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL10927053 0.79 CYP2A6 (0.46) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL11048187 0.78 CYP2A6 (0.46) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL10710471 0.78 HDAC3 (0.46) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL11154388 0.78 CYP2A6 (0.44) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL10371516 0.75 CYP2A6 (0.46) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL2494058 0.75 CYP2A6 (0.53) RAB9ACYP2A6ADRB2ASIC3LOXL2
SCHEMBL6481877 0.74 CYP2A6 (0.47) CYP2A6ADRB2ASIC3LOXL2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738035-B2 Hepatitis B antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2020-08-11 US disclosed
EP-0283522-B1 TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT IDEMITSU KOSAN COMPANY LIMITED (JP) 1991-02-27 EP disclosed
US-4932998-A LOW PHYTOTOXICITY FOR PADDY RICE PLANTS IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0283522-A1 TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT IDEMITSU KOSAN COMPANY LIMITED (JP) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738035-B2 Hepatitis B antiviral agents ZC3HAV1, ZC3HAV1L, HAVCR2 RAB9A 1062/4885CYP2A6 775/4885ADRB2 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.